更深缓解、更长生存——诺诚健华明诺凯®(坦昔妥单抗)全国首批处方落地

诺诚健华INNOCARE
Sep 25, 2025

诺诚健华(上交所代码:688428;香港联交所代码:09969)今天宣布,靶向CD19单抗明诺凯®(坦昔妥单抗,tafasitamab)近日在北京、上海、广东、黑龙江、福建、山东、广西、安徽、江西、湖北、浙江等全国多个省市医院开出首批处方,标志着这款创新药在中国正式进入临床应用阶段。坦昔妥单抗是全球首个且唯一获批治疗淋巴瘤的CD19单抗,也是中国首个获批治疗复发/难治性弥漫性大B细胞淋巴瘤(R/R...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10